Purpose: The Committee is charged with providing advice and guidance to the Director, Division of Healthcare Quality Promotion (DHQP), the Director, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), the Director, CDC, and the Secretary, Department of Health and Human Services, regarding (1) the practice of healthcare infection prevention and control; (2) strategies for surveillance, prevention, and control of infections, antimicrobial resistance, and related events in settings where healthcare is provided; and (3) periodic updating of CDC guidelines and other policy statements regarding prevention of healthcare-associated infections and healthcare-related conditions.

Matters to be Considered: The agenda will include the following updates: The Healthcare Personnel Guideline Workgroup; Isolation Precautions Guideline Workgroup; Dental Unit Waterlines Guideline Update; Division of Health Quality Promotion Updates; Review of Viral Hemorrhagic Fever Update; Pathogen Reduction Guidance Introduction; NHSN Update; **Recommendation Categorization** Framework Update. Agenda items are subject to change.

Public Participation

Oral Public Comment: This meeting will include time for members of the public to make an oral comment. Priority will be given to individuals who submit a request to make an oral public comment before the meeting according to the procedures below. All persons interested in making an oral public comment at the August 22, 2024 HICPAC meeting must submit a request between July 26, 2024, and August 12, 2024, at https://www.cdc.gov/hicpac/ meeting.html no later than 11:59 p.m., EDT, August 12, 2024, according to the instructions provided on the HICPAC website. If the number of persons requesting to speak is greater than can be reasonably accommodated during the scheduled time, CDC will conduct a lottery to determine the speakers for the scheduled public comment session. CDC staff will notify individuals regarding their request to speak by email by August 17, 2024.

The Director, Office of Strategic Business Initiatives, Office of the Chief **Operating Officer**, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal **Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024-17220 Filed 8-2-24; 8:45 am] BILLING CODE 4163-18-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

Meeting of the Advisory Committee on **Breast Cancer in Young Women**

AGENCY: Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS). **ACTION:** Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, the Centers for Disease Control and Prevention (CDC) announces the following meeting of the Advisory Committee on Breast Cancer in Young Women (ACBCYW). This meeting is open to the public, limited only by conference room space and web Conference lines (40 conference room and 60 web conference participant spaces available). Online registration is required.

DATES: The meeting will be held on September 13, 2024, from 8:30 a.m. to 4 p.m., EDT.

ADDRESSES: 4770 Buford Highway, Atlanta, Georgia 30341, Building 106, Room 1B. All ACBCYW Meeting participants must register for the meeting online at least 5 business days in advance at https://www.cdc.gov/ breast-cancer/php/advisory-committee/ index.html. Please complete all the required fields and submit your registration no later than September 6, 2024. Registered participants will receive access instructions before the meeting. All visitors are required to present a valid form of picture identification issued by a state, federal or international government. As required by the Federal Property Management Regulations, all persons entering in or on Federal controlled property and their packages, briefcases, and other containers in their immediate possession are subject to being x-raved and inspected. Federal law prohibits the knowing possession or the causing to be present of firearms, explosives and other dangerous weapons and illegal substances. Time will be available for public comment. The public is welcome

to submit written comments in advance of the meeting. Comments should be submitted in writing by email to acbcyw@cdc.gov. The deadline for receipt is September 10, 2024.

FOR FURTHER INFORMATION CONTACT:

Kimberly E. Smith, M.B.A., M.H.A., Designated Federal Officer, Advisory Committee on Breast Cancer in Young Women, National Center for Chronic **Disease Prevention and Health** Promotion, Centers for Disease Control and Prevention, 4770 Buford Highway NE, Mailstop S107-4, Atlanta, Georgia 30341. Telephone: (404) 498–0073; Fax: (770) 488-4760; Email: acbcyw@ cdc.gov.

SUPPLEMENTARY INFORMATION:

Purpose: The Advisory Committee provides advice and guidance to the Secretary, HHS; the Assistant Secretary for Health; and the Director, CDC, regarding the formative research, development, implementation, and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Advisory Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

Matters to be Considered: The agenda will include discussions on current topics related to breast cancer in young women. These will include Mental/ Behavioral Health, Sexual Health, Genetics and Genomics. and Provider Engagement. Agenda items are subject to change as priorities dictate.

The Director, Office of Strategic Business Initiatives, Office of the Chief **Operating Officer**, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal **Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,

Director, Office of Strategic Business Initiatives, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

[FR Doc. 2024-17219 Filed 8-2-24; 8:45 am] BILLING CODE 4163-18-P